The National Pharmaceutical Pricing Authority (NPPA) has issued Frequently Asked Questions (FAQs) clarifying the implementation of the Trade Margin Rationalisation (TMR) Order. The clarifications address mandatory Form V and Annexure-I submissions, MRP disclosures, government sales, sales returns, Patient Assistance Programme undertakings, existing stock management and eligibility for annual price increases.
NPPA has issued FAQs to address industry queries regarding the implementation of the TMR Order applicable to specified non-scheduled anticancer formulations.
Key points include:
- Manufacturers must submit Form V and Annexure-I through IPDMS within seven days of publication of the Order, irrespective of whether the MRP has changed.
- Newspaper advertisements are mandatory for products with reduced MRPs and must mention both pre-revised and revised prices.
- Government sales are defined as sales where the MRP is not printed or the pack is clearly labelled ‘For supply to Government; not for sale.’
- Sales returns cannot be adjusted while calculating net sales for PTS/PTD.
- TMR applicability extends to individual and combination formulations containing listed drugs, irrespective of strength, dosage form, route of administration or therapeutic use.
- PAP-related undertakings must initially be submitted before 29 October 2026 and whenever the MRP is revised.
- Recall, relabelling or restickering of existing stocks is not mandatory if price compliance is ensured at retailer level.
- Specified additional information may be submitted by 9 November 2026.
- Annual price increase eligibility under Paragraph 20(1) of DPCO, 2013 depends on the date of MRP revision.
